MOsteoDDProject ID: 728824
H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument
H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.4. - Active ageing and self-management of health
H2020-EU.3.1.6. - Health care provision and integrated care
PLATFORM FOR THE FRONTLINE OF OSTEOPOROSIS PREVENTION
Total cost:EUR 71 429
EU contribution:EUR 50 000
Topic(s):SMEInst-06-2016-2017 - Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well
Call for proposal:H2020-SMEINST-1-2016-2017See other projects for this call
Funding scheme:SME-1 - SME instrument phase 1
Osteoporosis is the most common reason for broken bones among elderly women. In the European Union, annual direct medical costs of fractures attributed to osteoporosis reach €36bn and are expected to rise to €76.9bn by 2050 in pace with the aging of population.
Early diagnosis and prevention is the key to reducing this burden and deliver more efficient health care to European citizens with new tools for doctors to better serve their patients.
Our mission at BONE VITAE (www.bonevitae.pl, Wroclaw, Poland) is to implement fast in-practice medical screening for early flags of osteoporosis with our patented osteoscanner ICT platform, the new frontline of prevention. Our non-invasive and painless bio-impedance spectroscopy technology is the only one that provides data on bone composition and chemical changes that mark the very start of osteoporosis onset, when there is still time to prevent it.
The Multi-electrode Osteoporosis Detection Device (MOsteoDD) platform is an exciting market opportunity for our company, a small, highly innovative venture with a powerful patented core technology seeking to enter the growth market of osteoporosis diagnostics worth $6–7 billion a year globally. Our patented six-electrode setup provides 95+% diagnostic accuracy results in less than 40 seconds, while the platform’s web service will analyse the device output and generate a written report for doctor’s use allowing pre-diagnosed patients to be referred for further scanning (DEXA) or for prescriptions to be issued.
The first version of the MOsteoDD osteoscanner has clinical validation in Poland and the CE mark (Conformité Européenne), and is currently at Minimum Viable Product (MVP) stage at Technology Readiness Level (TRL) 8. Current efforts are directed at maturing the platform to specific customer needs to reach the market with the support of SMEI funding.
EU contribution: EUR 50 000
MUCHOBORSKA, NR 18
54 424 WROCLAW